Lymphoma of childhood
-
Keywords:
lymphomaAbstract
-
Downloads
References
Wiangnon S, Veerakul G, Nuchprayoon I, Seksarn P, Hongeng S, Krutvecho T, et al. Childhood cancer incidence and survival
-2005, Thailand: study from the Thai pediatric oncology group. Asian Pac J Cancer Prev. 2011;12:2215-20.
Jitsupa Treetipsatit, Jassada Buaboonnam. Lymphoma. In: Jassada Buaboonnam, editor. Pediatric Oncology. Bangkok:
PrintAble. 2021:87-112.
Kharazmi E, Fallah M. Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries. Blood. 2015;126:1990-5.
Connors JM. Clinical manifestations and natural history of Hodgkin’s lymphoma. Cancer J. 2009;15:124-8.
Farruggia P, Trizzino A, Maringhini S, Grigoli A, Sapia C, D’Alessandro M, et al. Hodgkin lymphoma and nephrotic syndrome in childhood. Indian J Pediatr. 2010;77:1147-9.
Juneja M, Kaur S, Mishra D, Jain S. Ophelia syndrome: Hodgkin lymphoma with limbic encephalitis. Indian Pediatr. 2015;52:335-6.
Alavi S. Paraneoplastic neurologic syndromes in children: a review article. Iran J Child Neurol. 2013;7:6-14.
Srinivasan A, Satish G, Scott JX, Madhavan R, Sathiyasekaran M. Two Uncommon Paraneoplastic Neurological Syndromes in a Child With Hodgkin Lymphoma. J Pediatr Hematol Oncol 2016;38:473-5.
Adams HJ, Nievelstein RA, Kwee TC. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy. Ann Hematol. 2016;95:1-9.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059-68.
Thai Pediatric Oncology Group. Hodgkin Lymphoma. In: Surapon Wiangnon, Piti Techavichit, editor. National protocol in childhood
oncology 2018. Bangkok: Sahamitr Printing & Publishing Company Limited. 2018:145-72.
Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, et al. Outcomes in adolescents and young adults with
Hodgkin lymphoma treated on US cooperative group protocols: an adult intergroup (E2496) and children’s oncology group (COGAHOD0031) comparative analysis. Cancer. 2018;124:136-44.
Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R, et al. Preliminary results of the multicenter trial GPOH-HD 95
for the treatment of Hodgkin’s disease in children and adolescents: analysis and outlook. Klin Padiatr. 2003;215:139-45.
Appel BE, Chen L, Buxton AB, Hutchison RE, Hodgson DC, Ehrlich PF, et al. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children’s Oncology Group. J Clin Oncol. 2016;34:2372-9.
Shankar A, Hall GW, Gorde-Grosjean S, Hasenclever D, Leblanc T, Hayward J, et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin’s lymphoma - an Anglo-French collaborative report. Eur J Cancer. 2012;48:1700-6.
Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, et al. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012;307:2609-16.
Daw S, Hasenclever D, Mascarin M, Fernández-Teijeiro A, Balwierz W, Beishuizen A, et al. Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group. Hemasphere. 2020;4:e329.
Horton TM, Drachtman RA, Chen L, Cole PD, McCarten K, Voss S, et al. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a children’s oncology group study. Br J Haematol. 2015;170:118-22.
Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018;5:e450-61.
Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European group for blood and marrow transplantation. Blood. 2009;114:2060-7.
Smith RS, Chen Q, Hudson MM, Link MP, Kun L, Weinstein H, et al. Prognostic factors for children with Hodgkin’s disease treated with combined-modality therapy. J Clin Oncol. 2003;21:2026-33.
Mauz-Korholz C, Hasenclever D, Dorffel W, Ruschke K, Pelz T, Voigt A, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010;28:3680-6.
Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114:2051-9.
Choeyprasert W, Anurathapan U, Pakakasama S, Sirachainan N, Songdej D, Lertthammakiat S, Hongeng S. Pediatric non-Hodgkin lymphoma: characteristics, stratification, and treatment at a single institute in Thailand. Pediatr Int. 2019;61:49-57.
Pannone G, Zamparese R, Pace M, Pedicillo MC, Cagiano S, Somma P, et al. The role of EBV in the pathogenesis of Burkitt’s lymphoma: an Italian hospital based survey. Infect Agent Cancer. 2014;9:34.
Thorley-Lawson D, Deitsch KW, Duca KA, Torgbor C. The link between Plasmodium falciparum malaria and endemic Burkitt’s lymphoma-new insight into a 50-year-old enigma. PLoS Pathog. 2016;12:e1005331.
Ducassou S, Ferlay C, Bergeron C, Girard S, Laureys G, Pacquement H, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC58881, and EORTC 58951. Br J Haematol. 2011;152:441-51.
Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) international study group. Pediatr Blood Cancer. 2008;51:369-74.
Verma A, Pan Z. Pediatric-type follicular lymphoma. Hum Pathol Rep. 2022;27:300590.
Koo M, Ohgami RS. Pediatric-type Follicular Lymphoma and Pediatric Nodal Marginal Zone Lymphoma: Recent Clinical, Morphologic, Immunophenotypic, and Genetic Insights. Adv Anat Pathol. 2017;24:128-35.
Chaweephisal P, Sosothikul D, Polprasert C, Wananukul S, Seksarn P. Subcutaneous Panniculitis-like T-Cell Lymphoma with Hemophagocytic Lymphohistiocytosis Syndrome in Children and Its Essential Role of HAVCR2 Gene Mutation Analysis. J Pediatr Hematol Oncol. 2021;43:e80-4.
Zhen Z, Huang H, Lin T, Li Z, Zhen X, Xia Z, et al. Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents. Pediatr Blood Cancer. 2021;68:e28901..
Thai Pediatric Oncology Group. Non-Hodgkin Lymphoma. In: Surapon Wiangnon, Piti Techavichit, editor. National protocol in
childhood oncology 2018. Bangkok: Sahamitr Printing & Publishing Company Limited. 2018:145-72.
Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the children’s oncology group. Br J Haematol. 2013;162:792-801.
Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, et al. Results of the randomized international FAB/LMB96 trial
for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773-80.
Giulino-Roth L, O’Donohue T, Chen Z, artlett NL, LaCasce A, Martin-Doyle W, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017;179:739-47.
Mori T, Fukano R, Saito A, Takimoto T, Sekimizu M, Nakazawa A, et al. Analysis of Japanese registration from the randomized international trial for childhood anaplastic large cell lymphoma (ALCL99-R1). Rinsho Ketsueki. 2014;55:526-33.
Lowe EJ, Reilly AF. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137:3595-603.
Windsor R, Stiller C, Webb D. Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years. Pediatr Blood Cancer. 2008;50:784-7.
Kontny U, Oschlies I, Woessmann W, Burkhardt B, Lisfeld J, Salzburg J, et al. Non-anaplastic peripheral T-cell lymphoma in children and adolescents-a retrospective analysis of the NHL-BFM study group. Br J Haematol. 2015;168:835-44.
Attarbaschi A, Abla O, Arias Padilla L, Beishuizen A, Burke GAA, Brugières L, et al. Rare non-Hodgkin lymphoma of childhood and
adolescence: a consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma. Pediatr Blood Cancer. 2020;67:e28416.
Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute
lymphoblastic leukemia: a report from the children’s oncology group. Pediatr Blood Cancer. 2009;52:177-81.
Mossé YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children’s oncology group study. J Clin Oncol. 2017;35:3215-21.
Burke GAA, Beishuizen A, Bhojwani D, Burkhardt B, Minard-Colin V, Norris RE, et al. Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. Leukemia. 2020;34:2271-5.
Knörr F, Brugières L, Pillon M, Zimmermann M, Ruf S, Attarbaschi A, et al. Stem cell transplantation and vinblastine monotherapy for relapsed pediatric anaplastic large cell lymphoma: results of the international, prospective ALCL-relapse trial. J Clin Oncol. 2020;38:3999-4009.
Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16:223-30.
Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, et al. Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from children’s oncology group AALL0434. J Clin Oncol. 2020;38:3062-70.
Reiter A, Schrappe M, Ludwig W-D, Tiemann M, Parwaresch R, Zimmermann M, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95:416-21.
Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30:387-93.
Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children. N Engl J Med. 2020;382: 2207-19.
Mussolin L, Le Deley M-C, Carraro E, Damm-Welk C, Attarbaschi A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: long term results of the international ALCL99 trial. Cancers. 2020;12:2747.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Journal of Hematology and Transfusion Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
